GLSI
Greenwich Lifesciences IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$299.26M
P/E Ratio
—
EPS
$-1.46
Beta
1.53
52W High
$34.10
52W Low
$7.78
50-Day MA
$25.18
200-Day MA
$16.92
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 / neu-expressing cancers. The company is headquartered in Stafford, Texas.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-19.58M |
| Operating Margin | 0.00% |
| Return on Equity | -543.00% |
| Return on Assets | -254.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.16 |
| Price-to-Book | 136.96 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -21.23 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $13.85M |
| Float | $6.57M |
| % Insiders | 50.71% |
| % Institutions | 11.02% |
Historical Volatility
HV 10-Day
99.18%
HV 20-Day
87.91%
HV 30-Day
96.96%
HV 60-Day
97.92%
HV Rank
73.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($47.50 target)
2
BuyData last updated: 4/30/2026